• 1
    Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 26171.
  • 2
    Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003; 139: 50515.
  • 3
    Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29: 16947.
  • 4
    Chakravarty K, Elgabani SH, Scott DG, Merry P. A district audit on the management of polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1994; 33: 1526.
  • 5
    Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. Arthritis Rheum 2005; 53: 395403.
  • 6
    Gamez-Nava JI, Gonzalez-Lopez L, Davis P, Suarez-Almazor ME. Referral and diagnosis of common rheumatic diseases by primary care physicians. Br J Rheumatol 1998; 37: 12159.
  • 7
    Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26: 132632.
  • 8
    Cantini F, Salvarani C, Olivieri I. Erythrocyte sedimentation rate and C-reactive protein in the diagnosis of polymyalgia rheumatica. Ann Intern Med 1998; 128: 8734.
  • 9
    Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al, on behalf of the BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010; 49: 18690.
  • 10
    Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007; 57: 8039.
  • 11
    Dasgupta B, Matteson EL, Maradit-Kremers H. Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol 2007; 25: 1306.
  • 12
    Matteson EL. Clinical guidelines: unraveling the tautology of polymyalgia rheumatica. Nat Rev Rheumatol 2010; 6: 24950.
  • 13
    Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F, Maio T, Cimmino MA. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis 2001; 60: 10214.
  • 14
    Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005; 32: 6573.
  • 15
    Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47: 7339.
  • 16
    Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40: 15.
  • 17
    Dasgupta B, Hutchings A, Matteson EL. Polymyalgia rheumatica: the mess we are now in and what we need to do about it [editorial]. Arthritis Rheum 2006; 55: 51820.
  • 18
    Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A, et al, and members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008; 35: 2707.
  • 19
    Ferraccioli GF, Di Poi E, Damato R. Steroid sparing therapeutic approaches to polymyalgia rheumatica–giant cell arteritis: state of the art and perspectives. Clin Exp Rheumatol 2000; 18: S5860.
  • 20
    Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 4349.
  • 21
    Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis 2003; 62: 118994.
  • 22
    Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993; 52: 84750.
  • 23
    Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, et al, and members of the International Work Group for PMR and GCA. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011; 70: 44753.
  • 24
    Dasgupta B, Hutchings A, Hollywood J, Pease C, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life and diagnostic uncertainty in the first year in polymyalgia rheumatica: a prospective cohort study [abstract]. Rheumatology (Oxford) 2006; 45 Suppl 1: i170.
  • 25
    Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 159: 57784.
  • 26
    Cantini F, Salvarani C, Olivieri I, Niccoli L, Macchioni P, Boiardi L, et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum 2001; 44: 11559.
  • 27
    Cantini F, Niccoli L, Nannini C, Padula A, Olivieri I, Boiardi L, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005; 23: 4628.
  • 28
    Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60: 6419.
  • 29
    Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer; 2010. p. 5771.
  • 30
    Fabrigar LR, Wegener DT, MacCallum RC, Strahan EJ. Evaluating the use of exploratory factor analysis in psychological research. Psychol Methods 1999; 4: 27299.
  • 31
    Breiman L. Random forests. Machine Learning 2001; 45: 532.
  • 32
    Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routines. Department of Health Sciences Research Technical Report Series: no. 66. Rochester (MN): Mayo Clinic, 1997. p. 152.
  • 33
    Hastie T, Tibshirani R, Friedman J. Boosting and additive trees. In: The elements of statistical learning: data mining, inference, and prediction. 2nd ed. New York: Springer Science + Business Media; 2009. p. 33788.
  • 34
    Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, Crespo J, Pena M, Rodriguez-Valverde V, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 2004; 43: 6557.
  • 35
    Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 34852.
  • 36
    Nobunaga M, Yoshioka K, Yasuda M, Shingu M. Clinical studies of polymyalgia rheumatica: a proposal of diagnostic criteria. Jpn J Med 1989; 28: 4526.
  • 37
    Scheel AK, Matteson EL, Dasgupta B, Bruyn GA, Ohrndorf S, Werner C, et al. Reliability exercise for the polymyalgia rheumatica classification criteria study: the Oranjewoud Ultrasound Substudy. Int J Rheumatol 2009; 2009: 738931.
  • 38
    Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 2009; 169: 183950.